Go Back

Bio Ecosystem Science Updates

DeSci
Contents

Trials, pilots, and research are now happening in months.

Bio's pipeline of research projects is rapidly advancing. Track scientific progress across decentralized biotechs in the Bio Network.

Apply to launch a project with Bio → b̲i̲o̲.̲x̲yz̲/̲s̲c̲i̲e̲n̲t̲i̲s̲t̲s̲

See below the latest scientific updates in the Bio Network:

  1. VitaDAO: Portfolio now includes 16 longevity programs, including

• VitaSTEM: Stem cell rejuvenation research co-designed by @Aubrai_

• Cyclarity Therapeutics: Phase 1 clinical trial in progress.

• BE Therapeutics: Advancing brain-tissue graft models.

• Gero: Partnered with Chugai Pharma in a $250M deal.

• HDAX & Etheros Pharma: Focused on neurodegeneration and ROS inhibitors.

• Humanity App: Commercialized biological-age API.

New projects in mitochondrial biology and aging pathways are launching this quarter.

  1. Cerebrum DAO: Progress across five active neuroscience programs:

• Percepta: The clinical study protocol is finalized, and the IRB has been resubmitted with the pTau-217 biomarker.

• FissionBio: Mitochondrial ROS inhibitors have been validated in the first screen, and a second assay is currently underway.

• Transfidelity: The alpha-synuclein fidelity study is exceeding milestones, and a review has been accepted in Neural Regeneration Research.

• SK Channels: The replication study is completed, and we are evaluating next steps following mixed results.

𝗨𝗽𝗰𝗼𝗺𝗶𝗻𝗴: @NEURONGale project explores Galectin-3 inhibition as a novel Alzheimer’s therapy. Dr. Tomas Deierborg, Prof. of Neuroinflammation at Lund University, will lead testing of a small molecule in an in vivo mouse model, aiming to open a new path in Central Nervous System drug discovery.

  1. PsyDAO: Formalized IP and governance frameworks for psychedelic science and advanced numerous proposals through expert review and funding:

• Endo-DMTx (endogenous DMT pathway) led by Andrew Gallimore, Noonnautics & Dr. Chris McCurdy(university of florida, college of pharmacy)

• Next-Gen Empathogens (MDMA prodrugs): targeting initial in‐vitro and PK readouts ~6 months post-funding.

• BABS UCSF (human MRI study with Prof. Carhart-Harris): targeting high‐impact human data on enduring brain changes post‐first psilocybin use.

  1. ValleyDAO: Hempy enzyme platform has achieved lab-scale validation for hemp fiber treatment and is now preparing patent filings for two enzyme-based processes.

• Cocoa Zero and KardaForge programs have advanced toward pilot-scale testing for sustainable fats and metal recovery.

Next: patent filings this quarter and expanded IP Token integration via the Phlo AI research platform.

  1. Curetopia: Led by Dr. Ethan Perlstein and Paula Vujic, Curetopia advanced its ARS drug-repurposing pipeline using yeast-based screens.

Hit validation and animal studies are underway, with DAO-to-company translational pilots expected in 2026.

  1. HairDAO: Has completed several preclinical studies including:

• TRH Topical and Topical Thyroid Hormones have both been finalized and filed for provisional patents.

• The Dutasteride Delivery Vehicle, an optimized topical formulation, is nearing launch on Anagen.xyz.

• Twist1 and the in-house Olanzapine/Farnesol are progressing toward observational human studies.

HairDAO continues to integrate wet-lab R&D with its Anagen telehealth platform for data collection.

  1. AthenaDAO: Advanced four women’s health programs this year:

• FACC: A fertility small-molecule inhibitor showing in-vivo efficacy and improved metabolism in aged mice.

• OVARIA: An AI model predicting menopause transition risk, trained on UK Biobank data.

• ISR: Ovarian stress-response target validation is underway.

• LifeAhead: A spin-out has been formed; a provisional patent has been filed, and a pre-seed raise is in preparation. Proof-of-concept data is expected in Q4 2025–Q1 2026.

  1. Quantum Biology DAO: The Quantum Microscope project has completed instrument assembly and started magnetosensitivity experiments on engineered proteins.

A FAIR data pipeline and a public whitepaper are scheduled for early 2026.

The treasury surpasses $4.3M USD, providing a 30-month runway.

𝗧𝗵𝗲 𝗴𝗼𝗮𝗹: move science from experimentation to application faster & cheaper than legacy biotech.

Accelerating R&D across longevity, brain health, fertility, skin care & more.

Apply to launch a project with Bio → b̲i̲o̲.̲x̲yz̲/̲s̲c̲i̲e̲n̲t̲i̲s̲t̲s̲

https://www.bio.xyz/blog-posts/bio-ecosystem-science-updates